TAKEDA PHARMA (TKD.SG) (TKD STU) stock market data APIs
€25.765
0(0%)
as of July 4, 2025
Try our APIs with
free plan!
TAKEDA PHARMA (TKD.SG) Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for TKD.SG.
Prev. Close
25.765
Open
25.765
High
25.765
Low
25.765
52 wk Range
22.8694-27.7757
Market Cap
37 823 M
Dividends (Yield)
3.1353
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TAKEDA PHARMA (TKD.SG) data using free add-ons & libraries
Get TAKEDA PHARMA (TKD.SG) Fundamental Data
TAKEDA PHARMA (TKD.SG) Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TAKEDA PHARMA (TKD.SG) News
New
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Drugmakers have said they’re still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients. Continue Reading View Comments
Takeda Canada says Health Canada expands marketing authorization for HyQvia
Takeda (TAK) Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization wi...
Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to a...
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
